MiddleBrook Pharmaceuticals Inc. is expanding its IncreaseRx promotion program for Moxatag amoxicillin extended-release tablets.


MiddleBrook Pharmaceuticals, IncreaseRx, Moxatag, amoxicillin extended-release tablets, DoctorDirectory.com, Dave Becker, Jay Grobowsky








































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Middlebrook expands physician access to Moxatag samples

March 18th, 2010

WESTLAKE, Texas – MiddleBrook Pharmaceuticals Inc. is expanding its IncreaseRx promotion program for Moxatag amoxicillin extended-release tablets.

The company said Wednesday that under an agreement with DoctorDirectory.com Inc., its promotional partner for Moxatag (775 mg extended-release tablets), the broader IncreaseRx effort will incorporate physicians previously detailed by the company's field sales force and employ Web-based educational and promotional tactics to reach prescribers with targeted Moxatag sales and marketing messages.

"Under this expanded IncreaseRx program, physicians who previously received Moxatag samples and information from MiddleBrook field-sales representatives will be able to request samples and receive important product information electronically," Dave Becker, acting president and chief executive officer of MiddleBrook, said in a statement. "We will be able to reach more than 150,000 physicians across the nation through the expanded IncreaseRx program for Moxatag."

According to the company, IncreaseRx acts as a virtual contract sales organization, providing health care professionals with access to electronic sampling, electronic learning and online educational tools.

"We look forward to providing a promotional boost for Moxatag through IncreaseRx and providing increased access to Moxatag samples and information to physicians nationwide," commented Jay Grobowsky, president and CEO of DoctorDirectory, a marketing solutions company that specializes in providing Web-based access to health care professionals.

Moxatag is intended to provide a lower treatment dose, once-daily alternative to current penicillin and amoxicillin regimens for the treatment of adults and pediatric patients 12 years and older with tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes, according to Middlebrook. The tablets contain one immediate-release component and two delayed-release components.

Advertisement